Screener
aTyr Pharma ATYR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
FAQ
- What is aTyr Pharma's cash & equivalents?
- aTyr Pharma (ATYR) reported cash & equivalents of $16.16M in Q2 2026.
- How has aTyr Pharma's cash & equivalents changed year-over-year?
- aTyr Pharma's cash & equivalents decreased by 6.2% year-over-year, from $17.22M to $16.16M.
- What is the long-term trend for aTyr Pharma's cash & equivalents?
- Over 5 years (2020 to 2025), aTyr Pharma's cash & equivalents has grown at a -8.7% compound annual growth rate (CAGR), from $16.95M to $10.74M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about aTyr Pharma's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude